跳至主要内容
临床试验/NCT03183401
NCT03183401Unknown不适用

National Breast and Thyroid Screening After a Treatment Received Against a Cancer During Childhood

Institut National de la Santé Et de la Recherche Médicale, France1 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2017年7月9日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
2,000
试验地点
1
主要终点
follow of cancer screening recommendations

研究概览

简要总结

The DENACAPST programme represents an important initiative to provide near nation-wide roll-out of an important cancer surveillance program for childhood cancer survivors. The program is based on internationally recognized standards in cancer surveillance, which were developed by the International Guideline Harmonization Group (IGHG) with support of all relevant stakeholders in cancer survivorship research and clinical work in Europe, Canada and the United States and recognized French recommendations about breast screening for women at high risk of cancer.

With this programme, French centers organized themselves to provide to childhood cancer survivors adequate medical attention, which includes close medical surveillance for breast/thyroid cancer where appropriate, based on adequate risk stratification.

The aim of the study is to analyze if the recommendations about breast and thyroid cancer screening are followed in this population and secondly to provide more informations about these second cancers and about the screening.

详细描述

Every center which has patient at risk can participate. Main inclusion criteria : French childhood cancer survivor (5 years or more of delay with the treatment) - becoming adult - with a past history of radiotherapy at the age of 20 years or before, with a significant dose irradiation on the thyroid or the breast

The inclusion of patients are validated by one team

Thyroid screening programme is based on US each 2 years Breast screening programme is based mainly on MRI each year

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • childhood cancer survivor, and
  • treated with radiotherapy
  • health status compatible, and
  • have had a long-term follow-up consultation describing a personalized post-cancer plan and,
  • informed consent signed by patient
  • + Inclusion criteria for breast screening
  • being a woman and being 25 years or more for breast cancer screening, with a minimum delay of 8 years after radiotherapy, or
  • with a significant irradiation dose to the breast (Irradiation that delivered at least 10 Gy on at least part of the breast (v 5> 10 Gy) or on the mammary bud (v 100> 10 Gy) - (centrally validated dose) or received TBI (Total Body Irradiation)> 8 Gy according to a bi-fractioned scheme or> 6 Gy in single dose)
  • +Inclusion criteria for thyroid screening:
  • being a man or a woman and being 18 years or more for thyroid cancer screening with a minimum delay of 5 years after radiotherapy, and,
  • with a significant irradiation dose to the thyroid (Irradiation having delivered at least 3 Gy on the thyroid (v100> 3 Gy), or having received a TBI (Total Body Irradiation)> 2 Gy, and / or treatment with 131i-metaiodobenzylguanidine), and

排除标准

  • life expectancy <10 years due to other pathology
  • patient in regular follow-up within the framework of a genetic susceptibility (ex li fraumeni)
  • person placed under safeguard of justice
  • + exclusion criteria for breast cancer screening :
  • patient treated with bilateral mastectomy, or
  • patient being treated for breast cancer, or
  • patient initially treated with radiotherapy for breast cancer
  • + exclusion criteria for breast cancer screening :
  • Thyroidectomy, or
  • patient undergoing treatment or with a personal history of thyroid cancer

结局指标

主要结局

follow of cancer screening recommendations

时间窗: 2 years

number of persons at risk found percentage of persons at risk contacted who answered percentage of persons contacted, who answered, who accepted the screening

次要结局

  • description of breast cancer screening(2 years)
  • psycho social analyze(2 years)
  • description of thyroid cancer screening(2 years)
  • description of second cancers(2 years)

研究者

发起方
Institut National de la Santé Et de la Recherche Médicale, France
申办方类型
Other Gov
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验